Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The women's health initiative observational study

Thrombosis and Haemostasis

Volumn 93, Issue 6, 2005, Pages 1108-1116

  Langer, Robert D ^a   Pradhan, Aruna D ^b   Lewis, Cora E ^c   Manson, JoAnn E ^b   Rossouw, Jacques E ^d   Hendrix, Susan L ^e   LaCroix, Andrea Z ^f   Ridker, Paul M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c University of Alabama at Birmingham   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Coronary heart disease; Estrogens; Haemostatic factors; Inflammatory factors; Postmenopausal hormone therapy

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CONJUGATED ESTROGEN; D DIMER; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY RISK; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; INFLAMMATION; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PRIORITY JOURNAL; SELF REPORT; THROMBOSIS;

AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEMOSTASIS; HOMOCYSTEINE; HUMANS; INFLAMMATION MEDIATORS; LIPIDS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 20444473788     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-09-0608     Document Type: Article

References (50)

1. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
2. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
3. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Steering Committee. JAMA 2004; 291: 1701-12.
4. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522-9.
5. Hodis HN, Mack WJ, Azen SP et al. Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349: 535-45.
6. Waters DD, Alderman EL, Hsia J et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288: 2432-40.
7. The PEPI Investigators. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
8. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987; 114: 413-9.
9. Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
10. Castelli WP, Garrison RJ, Wilson PW et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-8.
11. National Institutes of Health, National Heart, Lung, and Blood Institute. Women's Health Initiative. Available at: www.nhlbi.nih.gov/whi/HT-en.htm.
12. Manson JE, Hsia J, Johnson KC et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523-34.
13. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43.
14. Meilahn EN, Kuller LH, Matthews KA et al. Haemostatic factors according to menopausal status and use of hormone replacement therapy. Ann Epidemiol 1992; 2: 445-55.
15. Nabulsi A, Folsom AR, White A. Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Eng J Med 1993; 328: 1069-75.
16. Scarabin PY, Plu-Bureau G, Bara L et al. Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 1993; 70: 584-7.
17. Vaughan DE, Rouleau JL, Ridker PM et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997; 96: 442-7.
18. Wright RA, Flapan AD, Alberti KG et al. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
19. van Baal WM, Emeis JJ, van der Mooren MJ et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000; 83: 29-34.
20. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071-8.
21. Caine YG, Bauer KA, Barzegar S et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68: 392-5.
22. de Valk-de Roo GW, Stehouwer CD, Meijer P et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 1999; 19: 2993-3000.
23. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 1994; 71: 420-3.
24. Saleh AA, Dorey LG, Dombrowski MP et al. Thrombosis and hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 1993; 169: 1554-7.
25. Shahar E, Folsom AR, Salomaa VV et al. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 1996; 93: 1970-5.
26. Koh KK, Mincemoyer R, Bui MN et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-90.
27. Walsh BW, Paul S, Wild RA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85: 214-8.
28. Straub RH, Hense HW, Andus T et al. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: a population-based study [see comments]. J Clin Endocrinol Metab 2000; 85: 1340-4.
29. Cushman M, Legault C, Barrett-Connor E et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999; 100: 717-22.
30. Cushman M, Meilahn EN, Psaty BM et al. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 1999; 19: 893-9.
31. Ridker PM, Hennekens CH, Rifai N et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999; 100: 713-6.
32. Barnabei VM, Phillips TM, Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Women's Health Gend Based Med 1999; 8: 1167-72.
33. van Baal WM, Smolders RG, van der Mooren MJ et al. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 1999; 94: 485-91.
34. Berger PB, Herrmann RR, Dumesic DA. The effect of estrogen replacement therapy on total plasma homocysteine in healthy postmenopausal women. Mayo Clin Proc 2000; 75: 18-23.
35. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998; 19: 61-109.
36. Ridker PM, Buring JE, Shih J et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
37. van Baal WM, Kenemans P, van der Mooren MJ et al. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thromb Haemost 1999; 81: 925-8.
38. Kvasnicka J Jr, Zivny J. Changes in serum levels of C-reactive protein and the soluble adhesion molecules, sE-selectin and sICAM-1, after transdermal 17-beta estradiol replacement. Ceska Gynekol 2001; 66: 161-5.
39. Herrington DM, Brosnihan KB, Pusser BE et al. Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women. J Clin Endocrinol Metab 2001; 86: 4216-22.
40. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619-25.
41. Hoibraaten E, Qvigstad E, Andersen TO et al. The effects of hormone replacement therapy (HT) on haemostatic variables in women with previous venous thromboembolism - results from a randomized, double-blind, clinical trial. Thromb Haemost 2001; 85: 775-81.
42. Teede HJ, McGrath BP, Smolich JJ et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 2000; 20: 1404-9.
43. Koh KK, Mincemoyer R, Minh NB et al. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336: 683-90.
44. Van Baal WM, Emeis JJ, Kenemans P et al. Short-term hormone replacement therapy: reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 1999; 29: 913-21.
45. Scarabin PY, Vissac AM, Kirzin JM et al. Elevated plasma fibrinogen and increased fibrin turnover among healthy women who both smoke and use low-dose oral contraceptives - a preliminary report. Thromb Haemost 1999; 82: 1112-6.
46. Lip GY, Blann AD, Jones AF et al. Effects of hormone-replacement therapy on haemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 1997; 134: 764-71.
47. Andersen LF, Gram J, Skouby SO et al. Effects of hormone replacement therapy on haemostatic cardiovascular risk factors. Am J Obstet Gynecol 1999; 180: 283-9.
48. Hak AE, Bak AA, Lindemans J et al. The effect of hormone replacement therapy on serum homocysteine levels in perimenopausal women: a randomized controlled trial. Atherosclerosis 2001; 158: 437-43.
49. Ventura P, Cagnacci A, Malmusi S et al. Continuous combined hormone replacement therapy with oral 17beta-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women. Menopause 2001; 8: 252-8.
50. Miyagawa K, Rösch J, Stanczyk F et al. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3: 324-7.